---
title: "Merck's pneumococcal vaccine Capvaxive approved for marketing, poised to challenge Pfizer's Prevnar market position"
description: "Merck's subsidiary, Capvaxive, a pneumococcal conjugate vaccine, has been approved by the U.S. Food and Drug Administration (FDA) and is poised to challenge Pfizer's Prevnar market position. Capvaxive"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/206538918.md"
published_at: "2024-06-18T00:18:07.000Z"
---

# Merck's pneumococcal vaccine Capvaxive approved for marketing, poised to challenge Pfizer's Prevnar market position

> Merck's subsidiary, Capvaxive, a pneumococcal conjugate vaccine, has been approved by the U.S. Food and Drug Administration (FDA) and is poised to challenge Pfizer's Prevnar market position. Capvaxive can prevent 80% of pneumococcal diseases, higher than Pfizer's Prevnar at 50%. The commercial prospects of Capvaxive depend on whether the CDC recommends the vaccine for adults over 50. Merck's vaccine business is strong, with the HPV vaccine Gardasil generating nearly $9 billion in revenue last year, and the pediatric pneumococcal conjugate vaccine Vaxneuvance expected to become a multi-billion dollar product. Merck is striving to increase new products, with Capvaxive complementing its vaccine business. Keytruda faces pricing pressure

According to the financial news app Zhitong Finance, Merck (MRK.US) subsidiary has received approval from the U.S. Food and Drug Administration (FDA) for its 21-valent pneumococcal conjugate vaccine Capvaxive (V116), which is used to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults aged 18 and older.

Studies have shown that Capvaxive can prevent bacterial strains that cause about 80% of pneumococcal diseases, while Pfizer's (PFE.US) 20-valent pneumococcal vaccine Prevnar has a rate of 50%. This means that Capvaxive may become the preferred vaccine for preventing pneumococcal diseases, challenging Pfizer's leading position in the market for such vaccines.

The commercial prospects of Capvaxive depend on the Centers for Disease Control and Prevention (CDC) in the United States, which will decide later this month whether to recommend Merck's vaccine to adults aged 50 and older.

Cantor Fitzgerald analyst Louise Chen stated that if the CDC favors Capvaxive, Merck may gain a competitive advantage over Pfizer's Prevnar. Data shows that Prevnar holds a market share of nearly 95%, bringing Pfizer over $6 billion in revenue annually, as people typically receive this type of vaccine only once in their lifetime.

As Merck's blockbuster cancer drug Keytruda, which contributes nearly half of the company's revenue, faces pricing pressure towards the end of this decade, Capvaxive serves as a complement to the company's strong vaccine business. Data indicates that Merck's HPV vaccine Gardasil brought in nearly $9 billion in revenue for the company last year, and its pediatric pneumococcal conjugate vaccine Vaxneuvance, approved in 2022, added $665 million in revenue last year, expected to become a product with sales reaching billions of dollars.

Ann Philbrick, Associate Professor in the Department of Family Medicine at the University of Minnesota, expressed excitement about the prospect of a more effective pneumococcal vaccine for healthcare providers. She stated, "Pneumonia causes a high incidence and mortality rate in the elderly, and we need to take any measures to prevent this situation."

### Related Stocks

- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)
- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 默克｜8-K：2025 财年 Q4 营收 164 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/274647604.md) |
| NewEdge Wealth LLC 增加了在默克公司 $MRK 的持股比例 | NewEdge Wealth LLC 在第三季度将其在默克公司的股份增加了 16.4%，目前持有 64,291 股，价值 543 万美元。其他机构投资者也增加了他们的持股。默克的股票开盘价为 121.83 美元，市值为 3023.9 亿美元 | [Link](https://longbridge.com/en/news/276442373.md) |
| 默沙东 2025 全年营收 650 亿美元，同增 1%，26 年营收指引 655 亿至 670 亿美元，低于预期｜财报见闻 | 默沙东发布 2025 年财报，全年营收 650 亿美元，同比增长 1%。预计 2026 年营收指引为 655 亿至 670 亿美元，低于市场预期。每股收益为 8.98 美元，同比增长 17%。Gardasil 疫苗销售面临挑战，2025 年 | [Link](https://longbridge.com/en/news/274693917.md) |
| 辉瑞在台湾开展新的 Elranatamab 研究，目标是收集现实世界的骨髓瘤数据 | 辉瑞公司（Pfizer Inc.，股票代码：PFE）正在台湾启动一项新的观察性研究，以评估其多发性骨髓瘤药物 elranatamab 在真实世界中的有效性。该研究旨在跟踪患者的治疗结果和治疗模式，尽管尚未开始招募参与者。此举预计将增强辉瑞的 | [Link](https://longbridge.com/en/news/276252273.md) |
| 这位辉瑞分析师以看空的基调开始覆盖；以下是周五的五大新启动 | 华尔街顶级分析师已对多家公司启动了覆盖。Baird 的 David Koning 对 Affirm Holdings (AFRM) 给予中性评级，目标价为 55 美元。Piper Sandler 的 Biren Amin 对 OKYO Ph | [Link](https://longbridge.com/en/news/276467088.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.